Sufentanil

( DrugBank: Sufentanil / KEGG DRUG: Sufentanil citrate, Sufentanil )


5 diseases
IDDisease name (Link within this page)Number of trials
11Myasthenia gravis1
22Moyamoya disease1
46Malignant rheumatoid arthritis1
IDDisease name (Link within this page)Number of trials
70Spinal stenosis5
280Huge arteriovenous malformation with cervicofacial or limb lesion1

11. Myasthenia gravis


Clinical trials : 525 / Drugs : 355 - (DrugBank : 80) / Drug target genes : 75 - Drug target pathways : 139 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

22. Moyamoya disease


Clinical trials : 36 / Drugs : 44 - (DrugBank : 26) / Drug target genes : 36 - Drug target pathways : 37 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

46. Malignant rheumatoid arthritis


Clinical trials : 4,743 / Drugs : 3,042 - (DrugBank : 389) / Drug target genes : 205 - Drug target pathways : 253 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

70. Spinal stenosis


Clinical trials : 146 / Drugs : 244 - (DrugBank : 71) / Drug target genes : 96 - Drug target pathways : 110 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

280. Huge arteriovenous malformation with cervicofacial or limb lesion


Clinical trials : 36 / Drugs : 41 - (DrugBank : 17) / Drug target genes : 12 - Drug target pathways : 169 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries